The PolyActiva product portfolio is composed of market validated products at different stages of development and with different risk / reward profiles.
We are evaluating multiple therapeutic areas and are pursuing product development where we believe our technology has clear competitive advantage. With have initiated clinical development for two of our ocular implant products, latanoprost ocular implant for the treatment of glaucoma, and levofloxacin ocular implant for prevention of endophthalmitis following ocular surgery. A phase Ia study in glaucoma concluded in Q2 2020 and a phase Ib dose ranging study started in Q2 2020. The phase Ia study of the levofloxacin ocular implant is due to commence in Q3 2020. Our remaining programs are at various stage of preclinical development. PolyActiva is open to partnerships to further the development of the pipeline and additional application of the platform.